RSS

Clinuvel

SCENESSE, a new drug developed by the Australian company Clinuvel, used for treating erythropoietic protoporphyria (EPP) - a rare photosensitivity disorder, has now been granted regulatory approval from the European Medicines Agency (EMA). more

News